Gut Microbiota in Cancer Immune Response and Immunotherapy.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and clinical concepts without systematic review methodology
PubMed 33674230 · doi:10.1016/j.trecan.2021.01.010
What was done
This review summarized literature regarding the bidirectional interactions between the gastrointestinal microbiome, host immune surveillance, tumor immune elimination and escape, and therapeutic responses to cancer immunotherapies such as immune checkpoint blockade.
What was found
The abstract provides conceptual and qualitative summaries rather than quantitative metrics or numbers. It describes that gut bacteria modulate host systemic immune homeostasis and tumor immune surveillance, while host immunity concurrently shapes the microbiome. The review notes that baseline microbiome signatures correlate with patient prognosis and heterogeneous immunotherapy efficacy, suggesting microbiome modulation as a potential adjunct to enhance efficacy or reduce toxicity.
Why it matters
Understanding host-microbiome-immune interactions highlights potential predictive biomarkers for immunotherapy response and supports testing microbiome-targeted interventions to improve cancer treatment outcomes.
Limits
The abstract reports no original experimental data, sample sizes, or quantitative effect estimates. As a narrative review, it lacks systematic search criteria, quality appraisal of cited studies, and risk-of-bias evaluation.
Cited by
- supports The gastrointestinal tract houses the primary concentration of the human body's immune system.